|
1
|
Wai PY and Kuo PC: Osteopontin: Regulation
in tumor metastasis. Cancer Metastasis Rev. 27:103–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrik D, Lavori PW, Cao H, Zhu Y, Wong P,
Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, et al:
Plasma osteopontin is an independent prognostic marker for head and
neck cancers. J Clin Oncol. 24:5291–5297. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mack PC, Redman MW, Chansky K, Williamson
SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and
Gandara DR: SWOG Lower osteopontin plasma levels are associated
with superior outcomes in advanced non-small-cell lung cancer
patients receiving platinum-based chemotherapy: SWOG Study S0003. J
Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Overgaard J, Eriksen JG, Nordsmark M,
Alsner J and Horsman MR; Danish Head and Neck Cancer Study Group, :
Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser
nimorazole in radiotherapy of head and neck cancer: Results from
the DAHANCA 5 randomised double-blind placebo-controlled trial.
Lancet Oncol. 6:757–764. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bache M, Kappler M, Wichmann H, Rot S,
Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, et al:
Elevated tumor and serum levels of the hypoxia-associated protein
osteopontin are associated with prognosis for soft tissue sarcoma
patients. BMC Cancer. 10:1322010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le QT, Sutphin PD, Raychaudhuri S, Yu SC,
Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC and Giaccia AJ:
Identification of osteopontin as a prognostic plasma marker for
head and neck squamous cell carcinomas. Clin Cancer Res. 9:59–67.
2003.PubMed/NCBI
|
|
7
|
Nordsmark M, Bentzen SM, Rudat V, Brizel
D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et
al: Prognostic value of tumor oxygenation in 397 head and neck
tumors after primary radiation therapy. An international
multi-center study. Radiother Oncol. 77:18–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hockel M, Schlenger K, Aral B, Mitze M,
Schaffer U and Vaupel P: Association between tumor hypoxia and
malignant progression in advanced cancer of the uterine cervix.
Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
|
|
9
|
Nordsmark M, Alsner J, Keller J, Nielsen
OS, Jensen OM, Horsman MR and Overgaard J: Hypoxia in human soft
tissue sarcomas: Adverse impact on survival and no association with
p53 mutations. Br J Cancer. 84:1070–1075. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Polat B, Wohlleben G, Katzer A, Djuzenova
CS, Technau A and Flentje M: Influence of osteopontin silencing on
survival and migration of lung cancer cells. Strahlenther Onkol.
189:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hahnel A, Wichmann H, Kappler M, Kotzsch
M, Vordermark D, Taubert H and Bache M: Effects of osteopontin
inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.
Radiat Oncol. 5:822010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hahne JC, Meyer SR, Kranke P, Dietl J,
Guckenberger M, Polat B and Hönig A: Studies on the role of
osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol.
189:1040–1048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zöller M: CD44: Can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marroquin CE, Downey L, Guo H and Kuo PC:
Osteopontin increases CD44 expression and cell adhesion in RAW
264.7 murine leukemia cells. Immunol Lett. 95:109–112. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu Y, Stamenkovic I and Yu Q: CD44
attenuates activation of the hippo signaling pathway and is a prime
therapeutic target for glioblastoma. Cancer Res. 70:2455–2464.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Denhardt DT, Giachelli CM and Rittling SR:
Role of osteopontin in cellular signaling and toxicant injury. Annu
Rev Pharmacol Toxicol. 41:723–749. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khan SA, Cook AC, Kappil M, Günthert U,
Chambers AF, Tuck AB and Denhardt DT: Enhanced cell surface CD44
variant (v6, v9) expression by osteopontin in breast cancer
epithelial cells facilitates tumor cell migration: Novel
post-transcriptional, post-translational regulation. Clin Exp
Metastasis. 22:663–673. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Christofori G: Changing neighbours,
changing behaviour: Cell adhesion molecule-mediated signalling
during tumour progression. EMBO J. 22:2318–2323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi J, Zhou Z, Di W and Li N: Correlation
of CD44v6 expression with ovarian cancer progression and
recurrence. BMC Cancer. 13:1822013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie JW, Chen PC, Zheng CH, Li P, Wang JB,
Lin JX, Lu J, Chen QY, Cao LL, Lin M, et al: Evaluation of the
prognostic value and functional roles of CD44v6 in gastric cancer.
J Cancer Res Clin Oncol. 141:1809–1817. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen P, Huang HF, Lu R, Wu Y and Chen YZ:
Prognostic significance of CD44v6/v7 in acute promyelocytic
leukemia. Asian Pac J Cancer Prev. 13:3791–3794. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yokota A, Ishii G, Sugaya Y, Nishimura M,
Saito Y and Harigaya K: Expression of exon v6-containing CD44
isoforms is related to poor prognosis of acute myelocytic leukemia.
Hematol Oncol. 16:131–141. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Naor D, Nedvetzki S, Golan I, Melnik L and
Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 39:527–579.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Günthert U: CD44 in malignant disorders.
Curr Top Microbiol Immunol. 213:271–285. 1996.PubMed/NCBI
|
|
26
|
Huh JW, Kim HR, Kim YJ, Lee JH, Park YS,
Cho SH and Joo JK: Expression of standard CD44 in human colorectal
carcinoma: Association with prognosis. Pathol Int. 59:241–246.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang XJ, Jiang H, Zhao XP and Jiang WM:
The role of a new CD44st in increasing the invasion capability of
the human breast cancer cell line MCF-7. BMC Cancer. 11:2902011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Phuc P, Nhan PL, Nhung TH, Tam NT,
Hoang NM, Tue VG, Thuy DT and Ngoc PK: Downregulation of CD44
reduces doxorubicin resistance of CD44+CD24- breast cancer cells.
Onco Targets Ther. 4:71–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jijiwa M, Demir H, Gupta S, Leung C, Joshi
K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, et al:
CD44v6 regulates growth of brain tumor stem cells partially through
the AKT-mediated pathway. PLoS One. 6:e242172011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao AC, Lou W, Dong JT and Isaacs JT: CD44
is a metastasis suppressor gene for prostatic cancer located on
human chromosome 11p13. Cancer Res. 57:846–849. 1997.PubMed/NCBI
|
|
31
|
Abetamann V, Kern HF and Elsässer HP:
Differential expression of the hyaluronan receptors CD44 and RHAMM
in human pancreatic cancer cells. Clin Cancer Res. 2:1607–1618.
1996.PubMed/NCBI
|
|
32
|
Hewitt RE, McMarlin A, Kleiner D, Wersto
R, Martin P, Tsokos M, Stamp GW and Stetler-Stevenson WG:
Validation of a model of colon cancer progression. J Pathol.
192:446–454. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang C, Xie J, Guo J, Manning HC, Gore JC
and Guo N: Evaluation of CD44 and CD133 as cancer stem cell markers
for colorectal cancer. Oncol Rep. 28:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flatmark K, Maelandsmo GM, Martinsen M,
Rasmussen H and Fodstad Ø: Twelve colorectal cancer cell lines
exhibit highly variable growth and metastatic capacities in an
orthotopic model in nude mice. Eur J Cancer. 40:1593–1598. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wohlleben G, Scherzad A, Güttler A,
Vordermark D, Kuger S, Flentje M and Polat B: Influence of hypoxia
and irradiation on osteopontin expression in head and neck cancer
and glioblastoma cell lines. Radiat Oncol. 10:1672015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Imamura T, Kikuchi H, Herraiz MT, Park DY,
Mizukami Y, Mino-Kenduson M, Lynch MP, Rueda BR, Benita Y, Xavier
RJ, et al: HIF-1alpha and HIF-2alpha have divergent roles in colon
cancer. Int J Cancer. 124:763–771. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang L, Zhao W, Zuo WS, Wei L, Song XR,
Wang XW, Zheng G and Zheng MZ: Silencing of osteopontin promotes
the radiosensitivity of breast cancer cells by reducing the
expression of hypoxia inducible factor 1 and vascular endothelial
growth factor. Chin Med J. 125:293–299. 2012.PubMed/NCBI
|
|
38
|
Song G, Cai QF, Mao YB, Ming YL, Bao SD
and Ouyang GL: Osteopontin promotes ovarian cancer progression and
cell survival and increases HIF-1alpha expression through the
PI3-K/Akt pathway. Cancer Sci. 99:1901–1907. 2008.PubMed/NCBI
|
|
39
|
Jiang C, Sun J, Dai Y, Cao P, Zhang L,
Peng S, Zhou Y, Li G, Tang J and Xiang J: HIF-1A and C/EBPs
transcriptionally regulate adipogenic differentiation of bone
marrow-derived MSCs in hypoxia. Stem Cell Res Ther. 6:212015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheng C, Zhang FJ, Tian J, Tu M, Xiong YL,
Luo W, Li YS, Song BB, Gao SG and Lei GH: Osteopontin inhibits
HIF-2α mRNA expression in osteoarthritic chondrocytes. Exp Ther
Med. 9:2415–2419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Könemann S, Malath J, Bölling T, Kolkmeyer
A, Janke K, Riesenbeck D, Hesselmann S, Nguyen TP, Diallo R,
Vormoor J, et al: Changed adhesion molecule profile of Ewing tumor
cell lines and xenografts under the influence of ionizing
radiation. Anticancer Res. 24:1637–1644. 2004.PubMed/NCBI
|
